1895 Mount Hope Avenue
Rochester, NY 14620
United States
585 271 2700
https://www.vaccinex.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Maurice Zauderer Ph.D. | Co-Founder, CEO, President & Director | 411.7k | N/A | 1947 |
Dr. Elizabeth E. Evans Ph.D. | COO and Senior VP of Discovery & Translational Medicine | 291.57k | N/A | 1973 |
Dr. Ernest S. Smith Ph.D. | Senior VP of Research & Chief Scientific Officer | 297.25k | N/A | 1972 |
Ms. Jill Sanchez CPA | Chief Financial Officer | N/A | N/A | 1972 |
Dr. John E. Leonard Ph.D. | Senior Vice President of Development | N/A | N/A | 1947 |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Vaccinex, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.